Provided by Tiger Fintech (Singapore) Pte. Ltd.

Simulations Plus

32.78
-0.0350-0.11%
Volume:137.23K
Turnover:4.49M
Market Cap:659.14M
PE:91.01
High:33.32
Open:33.11
Low:32.35
Close:32.81
Loading ...

Company Profile

Company Name:
Simulations Plus
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
245
Office Location:
42505 Tenth Street West,Lancaster,California,United States
Zip Code:
93534-7059
Fax:
- -
Introduction:
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.

Directors

Name
Position
Daniel Weiner
Board Chair
John K. Paglia
Director
Lisa LaVange
Director
Sharlene Evans
Director
Walter S. Woltosz
Director

Shareholders

Name
Position
Shawn O'Connor
Chief Executive Officer
Will Frederick
Chief Financial Officer & Chief Operating Officer
Daniel Szot
Chief Revenue Officer
Jenna Rouse
President, Adaptive Learning & Insights
Jill Fiedler Kelly
Co-President, Clinical Pharmacology & Pharmacometric Services
John A. DiBella
President, PBPK / Cheminformatics Solutions
Jonathan Chauvin
Co-President, Clinical Pharmacology & Pharmacometric Services
Murry Alper
President, Medical Communications
Steven Chang
President, Quantitative Systems Pharmacology Solutions